SEC Form 4 · accession 0001013606-19-000034
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Onopchenko
Officer — CEO and Director · Director
Period of report
Feb 13, 2019
Accepted (ET)
Feb 20, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF1 | $0.5803 | Feb 13, 2019 | A | 400,000 | A | Feb 13, 2020 | Feb 13, 2029 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1One-third of the options shall vest on February 13, 2020, and the remaining balance will vest in 24 equal monthly installments thereafter, such that the options will be fully vested on February 13, 2022.